News, Publications, and Investor Resources
News, Publications, and Investor Resources
UTILITY therapeutics is a biotechnology company focused on the US development and commercialization of 2 European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections.
Our approach is to identify exceptional candidates who meet urgent needs and draw on our expertise to expedite approval and make new options available to healthcare professionals and patients as quickly as possible.
News and Updates
News and Updates
September 29, 2021
UTILITY therapeutics to Present Data at IDWeek 2021
June 15, 2021
UTILITY therapeutics Preparing NDA Submission
April 1, 2020
UTILITY therapeutics announces leadership changes
September 19, 2018